Mydecine Innovations Group

Mydecine Innovations Group™ (MIG) is a start-up life sciences company focusing on mycology- (fungi) based psychedelic research, pharmaceutical/health products, and digital health solutions. MIG says they are “…positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™️ mushroom vitality products.”

Companies Comprising Mydecine

The parent company MIG is comprises three divisions:

Mydecine Health Sciences™ (MHS)

This division focuses on developing novel natural health products, including psychedelic medicines and mushroom-based products. MHS notes on their website that …”there are over 50,000 unique species of mushrooms, each containing different varieties of compounds that can be used for medicinal and wellness purposes.” However, the majority are not well understood and have not been thoroughly researched.

MHS goes on to say, “…recent studies have shown there are a variety of psychedelic compounds that are providing incredible relief in the fields of mental health issues. As promising as the early results have shown, these compounds are yet to be fully understood. Hoping to fill these gaps, MHS studies mushroom species and the compounds they contain, focusing on fungtional™ mushroom products and psychedelic medicines.

MHS maintains its headquarters in Denver, Colorado.

Mindleap Health™

MIG acquired the Mindleap Health digital telehealth platform in June 2020. The Mindleap division, “…helps people connect with mental health specialists that can empower them to thrive and develop habits for a healthy mind.” MIG says that what sets Mindleap apart is that it tracks emotions, mood, and habits along with the other functions of a digital health platform. The company says, “This is a paradigm shift to conventional mental health as Mindleap personalized support and users have the tools needed to track their progress and take control of their mental health.”

The Mindleap platform offers several features including,

  • Psychedelic aftercare, addiction, and holistic wellness services.
  • On-demand access to mental health programs.
  • Secure and confidential video sessions.
  • Critical tools for improved outcomes and personalized care.
  • High engagement features and gamification that improve the user experience.

Dr. Robin Carhart-Harris, leader of Imperial College London’s Centre for Psychedelic Research, serves on the MIG Scientific Advisory Board.

NeuroPharm, Inc.™ (NPI)

MIG acquired NPI in September 2020. This Canadian-based division focuses on research and development with an emphasis on providing Veteran-focused healthcare. NPI says it is “…developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations including Veterans, EMS personnel and other high-risk constituencies.”

NPI is exploring the little-understood world of magic mushroom compounds and the concept of the entourage effect between them. MIG says of NPIs strategy, “Even in the most potent psychoactive mushrooms, psilocybin is only 1-2% of the total mass. This means that as much as 99% of that mushroom is composed of other molecules. While many of those molecules may have no therapeutic value, some of them are pharmacologically active — either taken alone or in synergy with known psilocybin derivatives.”

NPI explains further than ingesting magic mushrooms the traditional way (eating them) does not give the user much control of their dosing, and hence, the amount of psilocybin that enters their body. They say that “Current methods for administering psilocybin fail to provide reliable dosing, which makes the resulting effects both inconsistent and unreliable.”

The solution they propose lies in formulating the active compounds in magic mushrooms into precise and consistent dosage forms. This way, users will know precisely what they are taking and how much. NPI says that formulating products with exact amounts of specific compounds “…will provide the desired active ingredients without any undesired compounds such as poisons and food-borne pathogens, such as bacteria or mold.

In addition, NPI is developing what they call Psilocybin Dosing Technology using evidence-based medicine. And, in collaboration with other business partners, NPI is also working on establishing psilocybin-based treatments to fulfill the unmet needs of high-risk constituencies. In August 2020, NeuroPharm announced that it was beginning the first-of-its-kind clinical trials using psilocybin-assisted therapy for treating PTSD (post-traumatic stress disorder) in Veterans.